Skip to main content
Protagenic Therapeutics, Inc.\new logo

Protagenic Therapeutics, Inc.\new — Investor Relations & Filings

Ticker · PTIX ISIN · US74365N2027 LEI · 549300KPBYAVJLPDKB70 US Professional, scientific and technical activities
Open in API
Filings indexed 678 across all filing types
Latest filing 2024-09-18 Regulatory Filings
Country US United States of America
Listing US PTIX

About Protagenic Therapeutics, Inc.\new

https://protagenic.com/

Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide-based therapeutics for stress-related disorders. The company's core technology is its TCAP (teneurin C-terminal associated peptide) platform, which utilizes neuropeptides to regulate the brain's stress response at a cellular level. This approach aims to counteract the 'Stress Feedback Loop' implicated in various neuropsychiatric and neurodegenerative conditions. Its lead drug candidate, PT00114, a synthetic TCAP, is being developed as a potential first-in-class treatment for disorders such as anxiety and depression.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It includes updates on clinical development milestones for a drug candidate and is signed by the CFO. The document length is 3347 characters, which is relatively short and typical for an 8-K filing. The content does not include full financial statements or detailed financial analysis but rather an update on other events. Form 8-K filings are regulatory filings used to report unscheduled material events or corporate changes. Therefore, this document fits best under the Regulatory Filings (RNS) category, which is the fallback for miscellaneous filings that do not fit other specific categories.
2024-09-18 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Q2 2024
2024-08-14 English
Delisting Announcement 2024
Delisting Announcement Classification · 100% confidence The document is a Form 8-K current report filed with the SEC by Protagenic Therapeutics, Inc. The key content is an Item 3.01 notice regarding a deficiency letter from Nasdaq about the company's failure to meet the minimum bid price requirement for continued listing. This is a formal announcement about a potential delisting event and the company's compliance status with Nasdaq listing rules. The document does not contain financial statements or detailed financial analysis, nor is it an earnings release or annual report. It is specifically an official notice about delisting risk and compliance with listing standards. Therefore, the appropriate classification is a Delisting Announcement (DLST). The document length is over 5,000 characters and contains substantive content about the delisting issue, not just a brief announcement or report publication notice, supporting this classification with high confidence.
2024-07-26 English
Regulatory Filings 2024
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify this document as any specific filing type. According to the fallback rule, when a document does not fit any specific category, it should be classified as a Regulatory Filing (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable. Therefore, the best classification is RNS with moderate confidence due to lack of readable content.
2024-06-18 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for public offering under the Securities Act of 1933. It includes detailed information about the types of securities to be offered, the maximum aggregate offering price, and the terms of the offering. The document is not an earnings release, annual report, or any other financial report but a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement or a certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2024-06-14 English
Delisting Announcement 2024
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC by Protagenic Therapeutics, Inc. dated May 22, 2024. The key content is an Item 3.01 notice regarding a deficiency letter from Nasdaq about non-compliance with the minimum stockholders' equity requirement, which is a notice of potential delisting. The document discusses the Nasdaq notification, the company's plan to regain compliance, and the possible consequences if the plan is rejected. This matches the definition of a Delisting Announcement (DLST), which is an official notice that the company's stock will be removed from an exchange or is at risk of removal. The document is not a full financial report, earnings release, or other types of filings. Therefore, the correct classification is DLST with high confidence.
2024-05-24 English

Browse filings by year

30 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.